Drug survival rates of biologic treatments in patients with psoriasis vulgaris
Author:
Publisher
Wiley
Subject
Dermatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2133.2011.10557.x/fullpdf
Reference5 articles.
1. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris;Gniadecki;Br J Dermatol,2011
2. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients;Brunasso;Acta Derm Venereol,2011
3. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials;Schmitt;Br J Dermatol,2008
4. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre;Warren;Br J Dermatol,2009
5. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials;Brimhall;Br J Dermatol,2008
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry;Journal of the American Academy of Dermatology;2023-11
2. Comparison of Survival and Retention Rates between Infliximab and Adalimumab for Psoriasis: 10-Year Experience at a Single Tertiary Center;Dermatology;2023
3. Infliximab drug survival in chronic plaque psoriasis: follow‐up of the product familiarisation program;Australasian Journal of Dermatology;2020-04-20
4. Drug survival in patients with psoriasis is associated with the availability of biologic medications;Journal of the European Academy of Dermatology and Venereology;2020-02-19
5. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study;Journal of Dermatological Treatment;2019-06-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3